High frequency of CDKN2A alterations in esophageal squamous cell carcinoma from a high‐risk Chinese population

Because previous studies have shown that loss of heterozygosity (LOH) is common on chromosome arm 9p in esophageal squamous cell carcinoma (ESCC) and that genetic alterations in CDKN2A and CDKN2B on 9p are also common, we sought to determine whether LOH and these genetic alterations are related. We performed LOH studies on chromosome bands 9p21–p22 and searched for genetic alterations of CDKN2A and CDKN2B in 56 ESCCs from a high‐risk Chinese population. Seventy‐three percent of patients were found to have LOH at one or more loci on chromosome bands 9p21–p22, and LOH occurred more frequently in patients with a family history of upper gastrointestinal cancer than in those with a negative family history (P = 0.01, global permutation test). CDKN2A mutations (point mutations, deletions, insertions) were observed in 25% (14 of 56) of cases, and the LOH pattern was significantly different for individuals with and without a CDKN2A mutation (P = 0.01, global test). Three new single nucleotide polymorphisms (SNPs) and 2 previously reported SNPs were identified in this group of patients. Intragenic allelic loss at polymorphic sites in CDKN2A was detected in 32% (18 of 56) of patients. Seven of the 56 (13%) cases exhibited what is considered classic evidence (n = 4) or showed potential evidence (n = 3) of biallelic inactivation. Only one alteration was observed in CDKN2B, G171A in the 5′ untranslated region. Both mutation and intragenic allelic loss in CDKN2A appear to play a role in the development of ESCC. ©2003 Wiley‐Liss, Inc.

[1]  Quan-hong Wang,et al.  Infrequent mutation in the BRCA2 gene in esophageal squamous cell carcinoma. , 2002, Clinical cancer research : an official journal of the American Association for Cancer Research.

[2]  A. Nakao,et al.  Molecular detection of p16 promoter methylation in the serum of patients with esophageal squamous cell carcinoma. , 2001, Clinical cancer research : an official journal of the American Association for Cancer Research.

[3]  N. Hu,et al.  Frequent inactivation of the TP53 gene in esophageal squamous cell carcinoma from a high-risk population in China. , 2001, Clinical cancer research : an official journal of the American Association for Cancer Research.

[4]  P. Pollock,et al.  Evidence for three tumor suppressor loci on chromosome 9p involved in melanoma development. , 2001, Cancer research.

[5]  D. Bishop,et al.  A germline deletion of p14(ARF) but not CDKN2A in a melanoma-neural system tumour syndrome family. , 2001, Human molecular genetics.

[6]  N. Hu,et al.  High frequency allelic loss on chromosome 17p13.3-p11.1 in esophageal squamous cell carcinomas from a high incidence area in northern China. , 2000, Carcinogenesis.

[7]  Hoguen Kim,et al.  p16 is a major inactivation target in hepatocellular carcinoma , 2000, Cancer.

[8]  S. Rockman,et al.  Methylation of exon 2 of p16 is associated with late stage oesophageal cancer. , 2000, Cancer letters.

[9]  Quan-hong Wang,et al.  Identification of novel regions of allelic loss from a genomewide scan of esophageal squamous‐cell carcinoma in a high‐risk Chinese population , 2000, Genes, chromosomes & cancer.

[10]  N. Hu,et al.  Allelic loss in esophageal squamous cell carcinoma patients with and without family history of upper gastrointestinal tract cancer. , 1999, Clinical cancer research : an official journal of the American Association for Cancer Research.

[11]  G. Yang,et al.  Mechanisms of inactivation of p14ARF, p15INK4b, and p16INK4a genes in human esophageal squamous cell carcinoma. , 1999, Clinical cancer research : an official journal of the American Association for Cancer Research.

[12]  H. Harada,et al.  Lymph node metastasis is associated with allelic loss on chromosome 13q12-13 in esophageal squamous cell carcinoma. , 1999, Cancer research.

[13]  G. Yang,et al.  Aberrant methylation of p16INK4a and deletion of p15INK4b are frequent events in human esophageal cancer in Linxian, China. , 1999, Carcinogenesis.

[14]  P. V. van Helden,et al.  p53 and p16/CDKN2 gene mutations in esophageal tumors from a high‐incidence area in South Africa , 1998, International journal of cancer.

[15]  D. Sidransky,et al.  Role of the p16 tumor suppressor gene in cancer. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[16]  K. Hemminki,et al.  Mutations in the CDKN2A ( p16INK4a ) gene in microdissected sporadic primary melanomas , 1998, International journal of cancer.

[17]  G. Thomas,et al.  Loss of heterozygosity on chromosome 9 and p16 (MTS1, CDKN2) gene mutations in esophageal cancers , 1997, International journal of cancer.

[18]  M. Lung,et al.  p16 tumor suppressor gene mutations in Chinese esophageal carcinomas in Hong Kong. , 1997, Cancer letters.

[19]  M. Imamura,et al.  Multiple types of aberrations in the p16 (INK4a) and the p15(INK4b) genes in 30 esophageal squamous‐cell‐carcinoma cell lines , 1997, International journal of cancer.

[20]  C. Sherr Cancer Cell Cycles , 1996, Science.

[21]  Carissa A. Sanchez,et al.  Allelic loss of 9p21 and mutation of the CDKN2/p16 gene develop as early lesions during neoplastic progression in Barrett's esophagus. , 1996, Oncogene.

[22]  Ruggero Montesano,et al.  Genetic alterations in esophageal cancer and their relevance to etiology and pathogenesis: A review , 1996, International journal of cancer.

[23]  M. Hollstein,et al.  Low frequency of p16/CDKN2 gene mutations in esophageal carcinomas , 1996, International journal of cancer.

[24]  J. Herman,et al.  Hypermethylation-associated inactivation indicates a tumor suppressor role for p15INK4B. , 1996, Cancer research.

[25]  G. Hannon,et al.  Intragenic mutations of CDKN2B and CDKN2A in primary human esophageal cancers. , 1995, Human molecular genetics.

[26]  Kathleen R. Cho,et al.  Frequency of homozygous deletion at p16/CDKN2 in primary human tumours , 1995, Nature Genetics.

[27]  J. Herman,et al.  5′ CpG island methylation is associated with transcriptional silencing of the tumour suppressor p16/CDKN2/MTS1 in human cancers , 1995, Nature Medicine.

[28]  A. Rustgi,et al.  MTS-1 (CDKN2) tumor suppressor gene deletions are a frequent event in esophagus squamous cancer and pancreatic adenocarcinoma cell lines. , 1995, Oncogene.

[29]  K. Kinzler,et al.  Deletion of p16 and p15 genes in brain tumors. , 1994, Cancer research.

[30]  J. Abraham,et al.  The MTS1 gene is frequently mutated in primary human esophageal tumors. , 1994, Oncogene.

[31]  T. Sugimura,et al.  Highly frequent homozygous deletion of the p16 gene in esophageal cancer cell lines. , 1994, Biochemical and biophysical research communications.

[32]  D. Sidransky,et al.  Rates of p16 (MTS1) mutations in primary tumors with 9p loss. , 1994, Science.

[33]  S. Mori,et al.  Frequent somatic mutation of the MTS1/CDK4I (multiple tumor suppressor/cyclin-dependent kinase 4 inhibitor) gene in esophageal squamous cell carcinoma. , 1994, Cancer research.

[34]  M. Skolnick,et al.  A cell cycle regulator potentially involved in genesis of many tumor types. , 1994, Science.

[35]  A. Okamoto,et al.  p16INK4 mutations and altered expression in human tumors and cell lines. , 1994, Cold Spring Harbor symposia on quantitative biology.

[36]  N. Hu,et al.  Family history of oesophageal cancer in Shanxi Province, China. , 1991, European journal of cancer.

[37]  Li Guang-Heng,et al.  A Survey of the Familial Aggregation of Esophageal Cancer in Yangcheng County, Shanxi Province , 1987 .

[38]  J. Li Epidemiology of esophageal cancer in China. , 1982, National Cancer Institute monograph.

[39]  L. Mingxin,et al.  Recent progress in research on esophageal cancer in China. , 1980 .

[40]  M. Li,et al.  Recent progress in research on esophageal cancer in China. , 1980, Advances in cancer research.